PharmiWeb Recruiter Blog

As we celebrate 25 years of PharmiWeb, we wanted to summarise some of the key ways we can help you to locate and engage top life science talent. Whether you’ve been partnering with us for years or are discovering us for the first time, this list of 25 services, features and free resources will ensure you’re getting the most out of our platforms.

Can you provide a brief outline of your role?

Can you provide a brief outline of your role?

Bracknell, UK. 9^th January 2024: PharmiWeb, the leading global life science news and jobs portal, is excited to announce it will be celebrating its 25^th anniversary this month. To commemorate this significant milestone, PharmiWeb will be running a month-long celebration campaign throughout January, recognising the company’s achievements over the past 25 years, and expressing gratitude to the loyal clients and candidates who have played a crucial role in its success.

As 2023 draws to a close, we wanted to take a moment to express our gratitude for your support during what has been a challenging year for the life science industry.

Healthcare intelligence organisation earns recognition as employer of choice and leading innovator in the clinical trial industry

• Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer
• To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio^® (avelumab) in the U.S. to the American Association for Cancer Research (AACR)

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.

Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases

• A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

Heidelberg, November 7, 2023. BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.

• Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche’s in-house assets
• Lead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbidities
• Under the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 million

Basel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.